HUYABIO International/Submits/HBI-8000 Monotherapy for Peripheral/T-cell Lymphoma for Regulatory Approval in Japan

HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).